Tumor human papillomavirus (HPV) status is a prognostic factor for oropharyngeal cancer, but classification methods are not standardized. Here we validate the HPV classification methods used in US cooperative group trials. Tumor DNA and RNA purified from 240 paraffin-embedded oropharyngeal cancers diagnosed from 2000 to 2009 were scored as evaluable if positive for DNA and mRNA controls by quantitative polymerase chain reaction (PCR). Eighteen highrisk (HR) HPV types were detected in tumors by consensus PCR, followed by HR-HPV E6/7 oncogene expression analysis by quantitative reverse transcriptase PCR. The sensitivity (S), specificity (SP), and positive (PPV) and negative predictive values (NPV) of p16 expression detected by immunohistochemistry (IHC) and HPV16 detected by in situ hybridization (ISH) were evaluated in comparison with HR-HPV E6/7 oncogene expression. Interrater agreement among 3 pathologists was evaluated by k statistics. Of 235 evaluable tumors, 158 (67%; 95% confidence interval, 61.2-73.3) were positive for HR-HPV E6/7 oncogene expression [HPV type 16 (92%), 18 (3%), 33 (3%), 35 (1%), or 58 (1%)]. p16 IHC had high sensitivity (S 96.8%, SP 83.8%, PPV 92.7%, and NPV 92.5%), whereas HPV16 ISH had high specificity (S 88.0%, SP 94.7%, PPV 97.2%, and NPV 78.9%) for HR-HPV oncogene expression. Interrater agreement was excellent for p16 (k = 0.95 to 0.98) and HPV16 ISH (k = 0.83 to 0.91). Receiver operating curve anal-ysis determined the cross-product of p16 intensity score and percentage of tumor staining to optimally discriminate HR-HPV E6/7-positive and HR-HPV E6/7-negative tumors. p16 IHC and HPV16 ISH assays show excellent performance, with high sensitivity and specificity, respectively. A new validated Hscore for p16 IHC assessment is proposed. Appropriate assay choice depends on clinical implications of a false-positive or false-negative test.
O ropharyngeal squamous cell carcinomas (OSCCs) are etiologically heterogenous, with one subset attributable to sexually acquired human papillomavirus (HPV) infection and another to chronic tobacco and alcohol use. 9, 33 In addition to distinct risk factor profiles, differences extend to prognosis. 2, 7, 21, 13, 20 Tumor HPV status is now considered the single greatest predictor of survival for patients with local/regionally advanced OSCC. Relative to HPV-negative patients, HPV-positive patients have an approximately 60% reduction in risk of death, corresponding to an absolute survival difference of approximately 30% at 5 years. 2, 7, 21, 13, 20 Despite these clinical advances, there are no commercially available, validated, and universally accepted tests for the determination of tumor HPV status. Methods commonly utilized include HPV detection by polymerase chain reaction (PCR), in situ hybridization (ISH), or the detection of p16 by immunohistochemistry (IHC) as a surrogate for the function of the high-risk (HR) HPV E7 protein. 5 Available algorithms in the literature for the research laboratory combine all 3 of these assays, 28, 29 but PCR detection of HPV in DNA purified from tumors is not likely to be feasible in most clinical laboratory settings.
A centralized laboratory evaluated tumor HPV status by p16 IHC and HPV16 ISH for the Eastern Cooperative Oncology Group (ECOG) 7 and Radiation Therapy Oncology Group (RTOG) trials 2 that helped to establish HPV as an important prognostic factor. The same laboratory is determining eligibility for ongoing trials in both cooperative groups. The laboratory methods used for p16 IHC and HPV16 ISH have shown strong agreement, 3 have demonstrated similar prognostic value, 2 utilize formalinfixed, paraffin-embedded (FFPE) material, and are feasible in a clinical pathology laboratory. 27 Here, we evaluate assay performance in comparison with HR-HPV E6/7 oncogene expression in tumors, the gold standard for categorizing a tumor caused by HPV.
MATERIALS AND METHODS

Case Selection and Pathology Review
A total of 240 FFPE biopsies from consecutive patients diagnosed with OSCC and available paraffin-embedded tumors in the hospital pathology archives were obtained from the Ohio State University, University of Chicago, University of California San Francisco, and Princess Margaret Hospitals (60 cases per site). Four-micrometer-thick sections were cut onto adherent slides that also contained tissue microarrays created from human tumor xenografts of cell lines with low (SiHa, Cat. No. HTB-35; ATCC, Manassas, VA) and high (CaSki, Cat. No. CRL-1550; ATCC) copy number HPV16 and an HPV-negative cell line (C33A, Courtesy of Ventana Inc., Tucson, AZ).
DNA and RNA Isolation
A study-specific standard operating procedure was used by all sites for serial sectioning of paraffin-embedded tumor blocks. New blades were used for each tumor sample. Sectioning included: hematoxylin and eosin (H&E) for verification of tumor in the specimen; ten 4mm-thick sections mounted on adherent slides; and two 10-mm-thick sections of "paraffin curls" placed in Eppendorf tubes for DNA and RNA isolation. DNA was isolated from each specimen using proteinase K digestion, phenol-chloroform extraction, and ethanol precipitation as previously described. 9 Total RNA was extracted using High Pure RNA Paraffin Kits (Roche, Mannheim, Germany) following the manufacturer's instructions. DNA and RNA quantity and purity were evaluated with a Nanodrop spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE). After DNase treatment, 0.2 to 0.3 mg of total RNA was reverse transcribed to cDNA using High Capacity RNA-to-cDNA Master Mix (Applied Biosystems, Carlsbad, CA) in 20 mL of reaction volume. Procedures on controls with no reverse transcriptase were performed in parallel for each sample.
HPV DNA Detection and Genotyping
HPV DNA detection and typing was performed using Inno-LiPA HPV Genotyping kits (Innogenetics, Gent, Belgium) following the manufacturer's instructions. The test is based on PCR amplification of a 65-bp fragment within the L1 open-reading frame of the HPV genome using broad-spectrum SFP10 biotinylated primers. Biotinylated amplicons are denatured and hybridized with HPV-type-specific oligonucleotide probes that are immobilized as parallel lines on membrane strips. The strip contains 28 HPV types (high-risk types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 , and 82; low-risk types 6, 11, 40, 43, 44, 54, 69, 70, 71, and 72) . After hybridization and stringent washing, streptavidin-conjugated phosphatase is added and bound to any biotinylated hybrid previously formed. Incubation with a BCIP/NBT chromogen yields a purple precipitate, and the results can be visually interpreted. Inno-LiPA HPV Genotyping hybridization was performed using an Au-toBlot 3000 H machine (MedTec Inc., Chapel Hill, NC).
HPV-type-specific Quantitative Real-time PCR and Reverse Transcriptase PCR HPV viral load in tumor tissue for type 16 was measured in all DNA samples (because of its frequent association with OSCC). HPV viral load and E6/7 RNA transcripts reverse transcribed to cDNA for types 18, 26, 31, 33, 35, 39, 51, 52 , and 58 were measured in tumors positive by Inno-LiPA HPV genotyping for corresponding HPV type(s) and for any samples positive for p16 but negative by Inno-LiPA in order to account for the possibility of deletion of the L1 region in tumors. HPV-typespecific PCR for types 31, 33, and 35 were performed using TaqMan quantitative real-time PCR (qPCR) in ABI 7300 real-time PCR systems (Applied Biosystems, Foster City, CA) as previously described. 9 In addition, primers and probes for amplification of HPV types 16, 18, 26, 39, 51, 52 , and 58 were designed to target the E6 and/or E7 region. The primers and probes were synthesized by Integrated DNA Technologies (Coralville, IA). Probes were labeled with 6-carboxyfluorescein (FAM) at the 5 0 end and with Black Hole Quencher-1 (BHQ1) at the 3 0 end. The sequences for primers (forward and reverse) and probes were as follows: HPV16 E6 (94 to 174 bp, GenBank accession no. K02718): 5 0 -GAGAACTGCAATGTTTCAGGACC-3 0 , 5 0 -TGTATAGTTGTTTGCAGCTCTGTGC-3 0 , and 5 0 -56-FAM/CAGGAGCGACCCAGAAAGTTACCACAG TT-3BHQ1-3 0 ; HPV-18 E7 (686 to 775 bp, GenBank accession no. GQ180792): 5 0 -GTGTGAAGCCAGAATT GAGC-3 0 , 5 0 -ACAAAGGACAGGGTGTTCAG-3 0 , and 5 0 -56-FAM/ACGACCTTCGAGCATTCCAGCA-3BHQ 1-3 0 ; HPV-26 E7 (559 to 628 bp, GenBank accession no. NC_001583): 5 0 -TTTGACAGCTCAGATGAGGA-3 0 , 5 0 -CTTCTTGTCCAGCTTGTCT-3 0 , and 5 0 -56-FAM/AT AATATGCGTGACCAGCAGGC-3BHQ1-3 0 ; HPV-39 E7 (608 to 676 bp, GenBank accession no. M62849): 5 0 -ACCCGACCATGCAGTTAATC-3 0 , 5 0 -ATTGTGTGA CGCTGTGGTTC-3 0 , and 5 0 -56-FAM/CCAACATCAA CTACTAGCCAGACGGGA-3BHQ1-3 0 ; HPV-51 E6 (378 to 462 bp, GenBank accession no. M62877): 5 0 -TGAAA TAGCGGGACGTTG-3 0 , 5 0 -GCTTTACACTTGGGTTT CG-3 0 , and 5 0 -56-FAM/TGCTGGCAACGTACACGA CAACG-3BHQ1-3 0 ; HPV-52 E7 (641 to 703bp, GenBank accession no. GQ472848): 5 0 -ACAGCTCAGATGAGGA GGA-3 0 , 5 0 -TGGCTTGTTTCTGCTTGTCC-3 0 , and 5 0 -56-FAM/ACAGATGGTGTGGACCGGCCA-3BHQ1-3 0 ; and HPV-58 E6 (489 to 548 bp, GenBank accession no. GQ472850): 5 0 -ATATTTCGGGTCGTTGGA-3 0 , 5 0 -TTT GTCTAGGTCGGGG-3 0 , and 5 0 -56-FAM/CGCTGTG CAGTGTGTTG-3BHQ1-3 0 . Standard curves for amplification reactions were generated in duplicate using a 5-fold dilution series (from 250,000 to 3.2 copies) of pUC57 vector (GenScript, Piscataway, NJ) containing the complete type-specific E6 and E7 regions in a background of human placental DNA (5 ng/mL). Each PCR reaction contained 1Â TaqMan universal PCR master mix (Applied Biosystems, Branchbury, NJ), 0.1 mmol of probe, 0.2 mmol of each primer, and 2 mL of purified tumor DNA or tumor RNA reverse transcribed cDNA. Amplification conditions included 1 cycle of 2-minute incubation at 501C (degradation of uracil-containing DNA) and 10-minute incubation at 951C, followed by 50 cycles of 15 seconds at 951C and 60 seconds at 601C. For all TaqMan qPCR assays, the cycle threshold of unknown samples was determined from an equation derived from a linear regression through the log cycle threshold of the standard curve according to the manufacturer's recommendation. Samples above the lower limit of reproducibility of the assays (for all, Z3 copies) were considered positive.
An estimate of the number of diploid genome equivalents (eg, cell number) in each sample was determined by TaqMan qPCR targeting on a single-copy human gene on chromosome 7, human endogenous retrovirus 3 (ERV3). 1 The 58-bp ERV3 fragment was amplified for 240 samples, and the reaction conditions were as previously published. 9 Briefly, 2 mL of purified tumor tissue DNA was analyzed. A standard curve was generated in duplicate from a 5-fold dilution series (from 150,000 to 1.92 cells) of a diploid human cell line, CCD-18Lu (ATCC). Results were reported as the number of human diploid genome equivalents of purified genomic DNA from tumor samples that were evaluated for HPV-type DNA by qPCR.
For RNA normalization, human ribosomal protein large, P0 (RPLP0) was chosen as a reference gene for quantitative reverse transcriptase-mediated PCR (qRT-PCR). Pilot studies have determined RPLP0 expression to be the most stable (out of 40 potential control genes) during histopathologic progression of cervical cancer (data not shown). The 73-bp RPLP0 fragment was amplified for 240 samples. The primers and probe sequences were as follows: 5 0 -ACGGGTACAAACGAGTCCTG-3 0 , 5 0 -GCCTTGACCTTTTCAGCAAG-3 0 , and 5 0 -56-FAM/ CCTTGTCTGTGGAGACGGAT-3BHQ1-3 0 . Standard curves for amplification reactions were generated in duplicate from a 5-fold dilution series (from 100,000 to 1.28 copies) of pOTB7 vector (Open Biosystems Products, Huntsville, AL) containing 1170 bp of RPLP0 mRNA fragment (Gene Bank BC019014) in a background of Salmon Sperm DNA (6 ng/mL; Invitrogen, Carlsbad, CA). Each PCR reaction contained 1 Â TaqMan universal PCR master mix, 0.4 mmol of probe, 0.5 mmol of each primer, and 2 mL of cDNA. Amplification conditions included 1 cycle of 2-minute incubation at 501C and 10-minute incubation at 951C, followed by 50 cycles of 15 seconds at 951C and 60 seconds at 621C. Results were reported as HPV type 16, 18, 26, 31 33, 35, 39, 52 , and 58 mRNA expression levels normalized to RPLP0 mRNA expression level as evaluated by qPCR.
p16 mRNA Expression Analysis by qRT-PCR
Samples were evaluated for mRNA expression of p16 by qRT-PCR with primers designed to amplify transcript variant 1 of the p16 gene (GenBank accession no. NM_000077.4): 5 0 -TGCCTTTTCACTGTGTTGGA-3 0 and 5 0 -AAATGCCCACATGAATGTGC-3 0 . The p16 probe sequence was 5 0 -(FAM)-AGGGCGTGAGTGCT CACTCCA-(BHQ1)-3 0 . Each PCR reaction contained 1Â TaqMan universal PCR master mix, 0.1 mmol of probe, 0.2 mmol of each primer, and 2 mL of cDNA with the following reaction conditions: 501C for 2 minutes to activate AmpErase UNG enzyme, 951C for 12 minutes to activate AmpliTaq Gold enzyme, followed by 50 cycles of 951C for 15 seconds and 601C for 60 seconds. Standard curves for amplification reactions were generated in duplicate using a 5-fold dilution series (from 150,000 to 1.92 cells) of CCD-18Lu human lung cell line (ATCC). Results were reported as p16 mRNA expression level normalized to RPLP0 mRNA expression level as evaluated by qRT-PCR.
p16 Immunohistochemistry
Automated p16 immunohistochemistry (IHC) stain using the monoclonal anti-p16INK4a (MTM Laboratories, Heidelberg, Germany) was carried out in the BenchMark XT (Ventana, Tucson, AZ) according to the manufacturer's IHC staining protocol. Briefly, slides were deparaffinized and retrieved at 951C for 30 minutes. 100 mL of prediluted monoclonal mouse anti-human p16INK4a were placed on the slides and incubated at 371C for 32 minutes. iView DAB detection kit (Ventana Medical Systems Inc., Tucson, AZ) was used as secondary detection. Slides were counterstained using hematoxylin and bluing reagent (Ventana, Tucson, AZ), and mounted under coverslips.
HPV16 In Situ Hybridization
HPV16 DNA was detected in paraffin-embedded tumor samples using the GenPoint catalyzed ISH signal amplification system for biotinylated probes (Dako, Carpinteria, CA). This signal amplification system can detect a single integrated copy of HPV16 DNA. 10 Briefly, tissue sections mounted onto slides were subjected to deparaffinization, heat-induced target retrieval using a steamer, and digestion with proteinase K (20 mg/mL; Roche Diagnostics, Indianapolis, IN) at room temperature. The slides were hybridized at 371C overnight with a biotinylated DNA probe that was specific for HPV16 (code Y1407; Dako) and then subjected to low-stringency and high-stringency washes, followed by signal amplification using a Tyramide Signal Amplification System kit (code K0620; Dako). The signal was developed by adding diaminobenzidine to the slides for 3 to 5 minutes and monitoring color change by light microscopy. The sections were counterstained with hematoxylin and mounted under coverslips.
Interpretation of Histopathology
H&E-stained slides were used to confirm the presence of tumor in the sample and to aid in assay interpretation. Slides were independently interpreted by 3 pathologists (R.C.J., M.W.L., and B.P-O.) in batches containing 40 cases with H&E the corresponding p16 IHC and the corresponding HPV16 ISH. Interpretation was recorded using a web-based reporting system. p16 IHC was scored as evaluable if strong and diffuse positivity was observed in the tissue microarray-positive control mounted on each slide. The highest intensity of p16 staining present in the tumor was scored by each pathologist on an ordinal score of 0 to 3, relative to the intensity of the positive (score 3) and negative (score 0) tissue microarray controls mounted on each slide. The percentage of tumor staining at the highest intensity was also estimated within 5% increments. Pathologists also scored tumors as staining positive or negative for p16 on the basis of the current standard of strong and diffuse nuclear and cytoplasmic staining in Z70% of the tumor. The H score was derived from the cross-product of the intensity score (0 to 3) and from the percentage of tumor staining at the highest intensity (0% to 100%).
HPV16 ISH-stained slides were scored as evaluable if punctate nuclear (SiHa) and diffuse nuclear (CaSki) staining was present in the positive control and was absent in the negative control tissue microarrays mounted on the slide. Tumors were scored on the following scale: 3+ (multiple confluent nuclear dots); 2+ (multiple punctate dots in tumor nuclei); 1+ (single punctate dots in tumor cells); and 0 (no staining). Cases were considered HPV16 positive for cases scoring 1+ or greater. 7 After independent interpretation, slides with discrepant categorical interpretation as p16 or HPV16 positive or negative were resolved by joint review for comparison with HPV E6/7 expression analysis.
Statistical Analysis
The study was powered to evaluate the interreader agreement among the 3 pathologists for a dichotomous categorization of an oropharyngeal tumor as positive or negative for p16 IHC or HPV16 ISH. A sample size of 206 cases provided 80% power to detect a Cohen k of 0.80 or higher, assuming a 0.50 probability of a positive test and a type I error rate of 0.0167 (Bonferroni adjustment to account for the 3 pairs of raters). The sample size was adjusted by 10% to 226 to account for the possibility of nonevaluable samples, and therefore each participating institution provided 60 cases (N = 240).
Differences between type-specific gold standard HPV-positive and HPV-negative samples with respect to their demographic and clinical characteristics were analyzed using contingency table w 2 tests. Nonparametric Mann-Whitney tests were used to determine the equality of medians in laboratory testing values. The Cohen k statistic was used to analyze interrater agreement for p16 IHC and HPV16 ISH testing among the 3 pathologists for all pairwise combinations and to analyze interassay agreement. Contingency tables were used to determine the sensitivity, specificity, and positive and negative predictive values [and 95% confidence intervals (CI)] for final p16 and HPV16 classifications compared with gold standard testing. All reported P values were 2-sided.
A receiver operating curve (ROC) analysis was carried out to examine and compare the classification accuracy on tumor HPV status among the 3 measures, including p16 IHC maximum tumor intensity, percentage of staining, and their cross-product (H score). For each of the 3 classification measures, the area under the curve (AUC) was calculated for each individual rater, and the optimal cutoff point was determined by the average sensitivities and specificities among the 3 raters. Stata 10.1 software (Stata-Corp, College Station, TX) was used for all analyses.
RESULTS
Study Population
A total of 240 cases of incident OSCC diagnosed from 2000 to 2009 were obtained for analysis on request from the collaborating pathologists and shipped by FedEx to the testing center. The demographic and clinical characteristics of the 235 cases that were both eligible and evaluable for HR-HPV E6/7 expression are shown in Table 1 . Three cases were found to be ineligible because of a diagnosis of recurrent (rather than incident) cancer (n = 1) or a primary tumor located in the oral cavity (n = 2). Two cases were not evaluable for viral expression analysis (see below).
HPV DNA and RNA Expression Analysis
An analysis of the DNA quantity and quality purified from tumor specimens determined 233 tumors to be evaluable by qPCR for the ERV3 gene. For ERV3, a median of 34,206 cells [interquartile range (IQR): 17,179 to 62,556] per sample were evaluated for HPV DNA. Median DNA yield was 5.74 mg (IQR: 1.92 to 13.78) per 10-mm-thick paraffin section with a median 260/280 nm ratio of 1.62 (IQR: 1.59 to 1.66).
When evaluated for the presence of HPV DNA by consensus primer PCR targeted to the viral capsid gene L1, 184 of 233 (78.3%; 95% CI, 73.0-83.6) cases were found to be positive. HPV16 was detected in the majority of positive samples (n = 170, 90.8%). Additional HR-HPV types detected included 18 (n = 6), 33 (n = 4), 35 (n = 2), 51 (n = 1), and 58 (n = 2). Two tumors were positive for >1 HR-HPV type, and 2 were positive for low-risk HPV type 6 or 11 and were not further evaluated for HPV E6/7 expression.
Expression of HR-HPV oncogenes E6/7 remains the gold standard for categorizing a tumor as caused by HPV. When samples were analyzed for expression of the endogenous control gene RPLP0 by qRT-PCR, 235 of 237 (99.2%) were found to be positive and therefore evaluable. The quantity and quality of total RNA extracted from tumor samples were good, with a median RNA yield of 3.39 mg (IQR: 1.33 to 9.38) per 10-mm-thick paraffin section and a median 260/280 nm ratio of 2.04 (IQR: 1.96 to 2.08) by spectrophotometry.
When evaluable samples were analyzed for expression of HPV16 E6/7 by qRT-PCR, 146 of 235 (62.1%; 95% CI, 55.9-68.4) were positive, including 2 samples negative for HPV16 by consensus PCR (consistent with deletion of the L1 region in tumors, Supplemental Table 1 Table 2 ). Viral copy number per cell was significantly higher among cases positive compared with those negative for viral oncogene expression (median 15.7 vs. 0 copies per cell, P < 0.001).
When compared with cases negative for HR-HPV E6/7 expression, positive cases were significantly more common among men and were more likely to be of tonsillar origin, early tumor stage (T1 and 2), and advanced nodal stage (N2 and 3) ( Table 1 ).
p16 IHC and HPV16 ISH Interpretation
On review, 231 of 235 cases assessed by p16 IHC had tumor present, had evaluable controls, and were considered evaluable ( Fig. 1 ). As shown in Table 2 , interrater agreement on interpretation of p16 expression as positive or negative in tumors was very high in all pairwise comparisons for the 3 raters (for all, k > 0.90). After resolution by joint review of tumors with discrepant interpretation, 70.2% (95% CI, 64.3-76.1) were found to be p16 positive.
All tumors were evaluated for p16 mRNA expression. Median values for p16 transcript expression were significantly higher for tumors positive compared with those negative for p16 IHC after consensus review (median: 92.0 vs. 4.1 copies per 1000 RPLP0) and for HR-HPV E6/7 expression (median: 93.5 vs. 5.8 copies per 1000 RPLP0).
On review, 232 of 235 cases evaluated by HPV16 ISH had tumor present on the slide, had evaluable positive and negative controls on the slide, and were therefore considered evaluable for this analysis (Fig. 1) . As shown in Table 2 , interrater agreement on interpretation of HPV16 ISH was extraordinarily high in all pairwise comparisons for the 3 raters (for all, k > 0.90). After resolution by joint review of tumors with discrepant interpretation, 60.9% (95% CI, 54.6-67.1) were found to be HPV16 ISH positive. Agreement between the p16 IHC and HPV16 ISH assays was very good (k = 0.70, Sup-plementary Tables 2 and 3 , Supplemental Digital Contents 2 and 3, http://links.lww.com/PAS/A120).
Comparison With the Gold Standard of High-risk HPV Oncogene Expression
We evaluated the performance of p16 IHC and HPV16 ISH in comparison with the gold standard test for HPV oncogene expression for type 16 alone and for all high-risk types ( Table 3 ). The p16 IHC assay had very high sensitivity for HPV16 E6/7 expression. Specificity was 72.1% for HPV16 E6/7 expression but increased to 83.8% when compared with HR-HPV E6/7 expression. The HPV16 ISH assay had very high sensitivity, specificity, and positive and negative predictive values in comparison with HPV16 E6/7 expression (Table 3 ). Assay sensitivity declined from 96.6% for HPV16 E6/7 expression to 88.0% in comparison with HR-HPV E6/7 expression.
When p16 IHC and HPV16 ISH tests were evaluated in combination (Table 3) , HPV E6/7 expression was present in 135 (98.5%) of 137 cases positive for both, in 18 (60%) of 30 p16-positive/HPV16 ISH-negative cases, 3 (50%) of 6 p16-negative/HPV16-positive cases, and in 2 (3.3%) of 61 cases negative for both. Therefore, a combination of HPV16 ISH positive and p16 IHC-positive had highest specificity in comparison with the gold standard test, with a false-positive rate of B3%. By contrast, use of a combination of either p16 IHC positive or HPV16 ISH positive will result in the highest sensitivity but will result in a false-positive rate of B19%.
Of the 27 (11.4%) cases with discrepant p16 IHC and HPV16 ISH analyses, 12 were found to be HR-HPV E6/7 positive. Analysis of the remaining 15 p16-positive tumors for HPV DNA or RNA revealed that all were negative for HPV 16, 18, 31, 33, 35, 45, 52, and 58. ROC analysis was performed to determine optimal cutoff points for p16 IHC interpretation in comparison with the gold standard HR-HPV oncogene expression (Table 4 ). For all 3 raters, the AUC for percentage staining was higher than that for intensity score, indicating that percentage staining as a single classification measure was better at discriminating the tumor HPV status. Significant differences in AUC were observed for both intensity score and percentage staining among pathologists (for both, P value for equality of areas <0.02). After averaging among the 3 raters, a p16 intensity score cutoff point of 2 on a scale of 0 to 3 was most sensitive, and a percentage staining cutoff point of 35% on a scale of 0% to 100% was most specific, for HR-HPV E6/7 expression ( Table 4 ). Use of the cross-product of these measures (H score) resulted in a better clarification of tumor HPV status. An optimal H score cutoff point of 60 on a scale of 0 to 300 yielded an average sensitivity of 91.6% and specificity of 90.4% for HR-HPV oncogene expression.
DISCUSSION
The p16 IHC and HPV16 ISH assays used in past and ongoing cooperative cancer group trials in the United States for classification of tumor HPV status have excellent assay performance, with high sensitivity and specificity, respectively, for expression of HR-HPV E6/7 oncogenes and excellent interrater agreement on interpretation. The sensitivity of HPV16 ISH is limited by the presence of a small proportion of HR-HPV types other than HPV16 in tumors, and the specificity of p16 is limited by the presence of p16-positive tumors that are without evidence of HPV DNA or E6/7 expression.
Determination of HPV status for OSCC is rapidly becoming the standard of care, with the majority of pathologists reporting current 1 or future intent 26 to evaluate all tumors. Tumor HPV status is now accepted as a strong, independent prognostic factor for oropharynx cancer, 2,8 is predictive of response to treatment with cisplatin induction chemotherapy 7, 35 and radiotherapy, 5 and can aid in the differential diagnosis of cystic neck lesions 6 and localization of an unknown primary. 3, 16 The importance of HPV testing is underscored by the increasing number of organizations recommending its use, including the National Comprehensive Cancer Network, 19 The College of American Pathologists, and The Collaborative Stage Data Collection System, utilized by associations such as the American Joint Committee on Cancer and Surveillance Epidemiology and End Results program. Unfortunately, there is no current standard for *Due to rater evaluation of tumor missing on IHC slide: rater 1/2, n = 231; rater 1/3, n = 232; rater 2/3, n = 231. wDue to rater evaluation of tumor missing on ISH slide: rater 1/2, n = 233; rater 1/3, n = 232; rater 2/3, n = 232.
Am J Surg Pathol Volume 36, Number 7, July 2012 Oropharyngeal Cancer HPV Status Determination testing or interpretation of HPV detection assays, and each assay has technical limitations. However, p16 IHC and HPV16 ISH are currently preferred for prognostication, because these methods have been used in the clinical trials that established HPV as an important prognostic factor for these cancers. 3, 7 In addition, these assays provide comparable prognostic value for the detection of HPV16 E6/7 expression. 25 Previous analyses have reported that as many as 50% of HPV DNA-positive tumors are negative for E6/7 mRNA expression. 34 In our analysis, 14% of HPV DNApositive tumors were negative for HR-HPV E6/7 expression and had very low HPV DNA viral load, arguing against the use of PCR alone for classification of HPV status. The HPV DNA PCR-positive/p16 IHC-negative tumor once considered a biologically unique class of tumor is likely explained by these false-positive tests. 34 HPV ISH using either type-specific or probe "cocktails" can be performed on clinical FFPE and localizes virus topographically to tumor. Although our HPV16 ISH assay has single-copy sensitivity and excellent assay performance in comparison with HPV16 E6/7 expression, it is type specific, nonautomated, technically difficult to perform, and not commercially available. Our findings are difficult to compare with other recent analyses of HPV ISH assay performance because of differences in laboratory methodology and use by other investigators of a gold standard of HPV DNA detection by PCR alone. 9, 29, 32 However, as recently reported by Schlecht et al, 23 commercially available assays by Ventana (INFORM HPV-III Fam16B) and Dako (HPV16/18) appeared to have less impressive assay performance when compared with HPV16 E6/7 expression (AUC: 0.48 to 0.69).
An increasingly common alternative to HPV ISH is determination of p16 protein expression by IHC. In HPVassociated cancers, p16 is frequently overexpressed because of inactivation of pRb by the HR-HPV E7 oncoprotein and consequent release of pRb-mediated negative regulation of p16. 15 In the histopathologic progression of cervical cancer, p16 expression increases with severity of dysplasia and cancer and is a possible adjunct to HPV testing for a triage of mild versus moderate or greater dysplasia. 11, 24 However, as is the case for oropharynx cancers, lack of standardization of testing and interpretation of p16 IHC has in part delayed introduction into the clinic. 31 Comparable assay performance for p16 to that observed here has been reported previously, 23, 29 even when a different monoclonal antibody to p16 was used. Similarly, a high agreement on interrater interpretation has also been reported, 23, 29 indicating the familiarity of pathologists with interpretation of IHC assays. The currently recommended cutoff point for defining a positive p16 IHC assay-strong and diffuse nuclear and cytoplasmic staining of Z70% of the tumor-was largely experientially determined. 3 In this report, the optimal cutoff point was evaluated on the basis of the area under the ROC curve in comparison with HR-HPV E6/7 expression. Our cutoff point for staining intensity agreed with the empirically determined cutoff point of Z2. However, the optimal cutoff point for percentage staining was lower at Z35%. The H score cutoff point of 60 indicates that a tumor with diffuse low-intensity nuclear and cytoplasmic p16 staining in the majority of the tumor is a true positive, likely because of the effect of highly variable tumor fixation on the intensity of staining. The effect of this alternate cutoff point for interpretation of p16 IHC on survival analyses remains to be evaluated.
Test results for p16 IHC and HPV16 ISH had very good agreement. As previously reported, 2,4,27 approximately 15% of cases have discordant test results and are most frequently p16 positive and HPV ISH negative. Our data indicate that half of these are attributable to HPV types other than type 16. The resulting misclassification caused by the type specificity of our ISH assay explains the relative increase in absolute survival difference for p16positive versus p16-negative patients as compared with HPV16-positive versus HPV16-negative patients reported in the analysis of RTOG 0129 by Ang et al. 2 As noted in the discussion of the paper by Ang and colleagues, the wide-spectrum HPV ISH assay used in that analysis has unknown sensitivity for non-16 HPV types. These data have, unfortunately, been misinterpreted as evidence that p16 expression has prognostic significance independent of tumor HPV status for OSCC. Indeed, a recent report that p16 had independent prognostic import was complicated by the fact that subsequent testing revealed the majority of p16-positive and HPV-negative tumors to have HPV E6/7 expression. 14, 18, 32 p16 expression has also been recommended as a means by which to discriminate tumors in which HPV does and does not play a biologically meaningful role. 34 Although only comprising B3% of OSCC cases overall, here we demonstrate that HPV ISH-positive/ p16-negative tumors have HR-HPV E6/7 expression and are therefore etiologically associated with HPV. The specific molecular alterations that underlie p16 overexpression in the absence of demonstrable HPV expression and the lack of p16 expression in the presence of HR-HPV E6/7 expression are not yet defined, and the clinical outcome of patients with true discordant results remains unknown 18 because of small subsets in correlative studies within clinical trials to date. It is noteworthy that p16 expression is being evaluated as a possible prognostic factor in cancers at numerous anatomic sites, including lung, 30 oral cavity, 17 and prostate, 12 among others. 22 Our data should not be used to guide the interpretation of p16 IHC testing at nonoropharyngeal sites.
The appropriate assay to use either singly or in combination will depend upon the clinical implications of a false-positive or false-negative test. Our analyses indicate that p16 IHC or HPV16 ISH alone may result in misclassification of approximately 17% to 19% of tumors, with the majority for each test being false positive and false negative, respectively. If used for clinical trial eligibility, p16 IHC testing alone will facilitate enrollment of patients without a true diagnosis of HPV-associated cancer, and the effect of the inclusion of these patients on clinical trial design and outcomes is unpredictable. For clinical trials evaluating "deintensification" strategies for patients with HPV-associated OSCC, combined p16 IHC and HPV16 ISH is necessary to provide the high specificity required to avoid possible undertreatment of patients without a diagnosis of HPV-associated OSCC. Combined testing also aids in prognostication, given the outcome of patients with concordant tests is clear, whereas either test alone may result in erroneous communication regarding the patient's true prognosis. By contrast, either assay can be used for stratification of patients within clinical trials to ensure arms are balanced by p16 or HPV status.
In conclusion, the laboratory methods currently used to determine eligibility for RTOG and ECOG trials have high sensitivity and specificity for OSCC caused by HPV. A validated, commercial assay is clearly needed, as these assays are increasingly being used for decision making for the individual patient. The optimal assay would combine the sensitivity of p16 IHC with the specificity of HPV ISH, with an expanded HPV probe cocktail to account for HR-HPV types other than HPV16.
